Abstract | BACKGROUND: Opportunistic fungal infections are a major cause of morbidity and mortality in neutropenic cancer patients and antifungal therapy is used both empirically and therapeutically in these patients. OBJECTIVES: SEARCH METHODS: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2014, Issue 1 2014), MEDLINE (to January 2014). Letters, abstracts and unpublished trials were accepted. Contact was made with trial authors and industry. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Data on mortality, invasive fungal infection, colonisation, use of additional (escape) antifungal therapy and adverse effects leading to discontinuation of therapy were extracted independently by two review authors. MAIN RESULTS: AUTHORS' CONCLUSIONS:
|
Authors | Karsten Juhl Jørgensen, Peter C Gøtzsche, Christina S Dalbøge, Helle Krogh Johansen |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 2
Pg. CD004707
(Feb 24 2014)
ISSN: 1469-493X [Electronic] England |
PMID | 24563222
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Antifungal Agents
- Liposomes
- Pyrimidines
- Triazoles
- Amphotericin B
- Fluconazole
- Voriconazole
|
Topics |
- Amphotericin B
(adverse effects, therapeutic use)
- Antifungal Agents
(adverse effects, therapeutic use)
- Aspergillosis
(drug therapy)
- Fluconazole
(adverse effects, therapeutic use)
- Humans
- Liposomes
- Mycoses
(drug therapy, mortality)
- Neoplasms
(complications)
- Neutropenia
(drug therapy, microbiology, mortality)
- Opportunistic Infections
(drug therapy, microbiology, mortality)
- Pyrimidines
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Triazoles
(adverse effects, therapeutic use)
- Voriconazole
|